Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Karen Maloney

Dermatology Miami, FL Medical Doctor

NPI 1912918186 CMS profile 1186480

8740 N Kendall Dr Ste 101, Miami, FL 33176

Open in the dashboard

General payments

$1,650

86 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Karen Maloney of Miami, FL is reported in the CMS Open Payments database as having received $1,650 across 86 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 42nd percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $67 2
2023 General $46 2
2022 General $98 5
2021 General $577 29
2020 General $363 21
2019 General $498 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Karen Maloney
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Karen Maloney were reported at $67. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Karen Maloney Dermatology median Middle half National median
2019 $498 $454 $129–$1,240 $163
2020 $363 $235 $81–$756 $114
2021 $577 $377 $108–$1,108 $132
2022 $98 $514 $143–$1,391 $149
2023 $46 $607 $159–$1,674 $160
2024 $0 $751 $204–$1,903 $164
2025 $67 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $295 16 payments
  2. Amgen Inc. $169 9 payments
  3. AbbVie, Inc. $129 6 payments
  4. Novartis Pharmaceuticals Corporation $127 7 payments
  5. UCB, Inc. $120 6 payments
  6. Sun Pharmaceutical Industries Inc. $112 5 payments
  7. Dermira, Inc. $89 5 payments
  8. Sanofi-Aventis U.S. LLC $79 2 payments
  9. Janssen Biotech, Inc. $77 5 payments
  10. Lilly USA, LLC $76 4 payments
  11. Other $377 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,571 84 payments
  2. Education $79 2 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $247 12 payments
  2. Otezla $132 7 payments
  3. Cimzia $120 6 payments
  4. SKYRIZI $108 5 payments
  5. ILUMYA $97 4 payments
  6. LIBTAYO $97 4 payments
  7. TALTZ $76 4 payments
  8. COSENTYX $71 4 payments
  9. QBREXZA $66 4 payments
  10. DUPIXENT Immunology $64 3 payments
  11. Other $879 51 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

161

Median for Dermatology: 534

Drug cost

$5,225

Median for Dermatology: $67,151

Branded share of claims

0%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fluorouracil Generic 39 $2,378
Clobetasol Propionate Generic 53 $1,976
Triamcinolone Acetonide Generic 28 $422
Ketoconazole Generic 30 $376
Mupirocin Generic 11 $74

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$43,892

Medicare's payments for the services billed

Medicare patients

337

Average age 75

Services billed

834

188 women, 149 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 45%
Diabetes 26%
Ischemic heart disease 21%
Chronic kidney disease 20%
Osteoporosis 17%
Depression 16%
Atrial fibrillation 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

86 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record